Evidence map›Paper›PMID 38991191›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Future of Dendritic Cell-Based Approaches in Pancreatic Cancer.

Ashwin Somasundaram, Jen Jen Yeh

Abstract readEditorialComment
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ashwin SomasundaramLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Jen Jen YehLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0003-2542-6211

Funding

SToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gianpietro Dotti · 2022 to 2026
$12.9M
Integrating tumor and stroma to understand and predict treatment responseU01CA274298 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Naim Ur Rashid, Susan Tsai · 2022 to 2026
$4.7M
Targeted EGFR for basal subtype pancreatic cancerR01CA288145 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARY L. JOHNSON, Jen Jen Yeh · 2024 to 2026
$1.9M
Pathway, Network and Spatiotemporal Integration of Cancer Genomics DataU24CA264027 · NCI · PRINCETON UNIVERSITY · PI RAPHAEL, BENJAMIN, YEH, JEN JEN · 2021 to 2025
$1.5M
The role of IL6-induced LAG3 as a resistance mechanism to PD1 blockade in NSCLC patientsK08CA259342 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ashwin Somasundaram · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA259342NCI NIH HHS P50 CA257911NCI NIH HHS R01 CA288145NCI NIH HHS U01 CA274298NCI NIH HHS U24 CA264027
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dendritic CellsPancreatic NeoplasmsCancer VaccinesHumansImmunotherapyCancer Vaccines

Identifiers

PMID38991191
PMCPMC11377165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.